Vascular Therapies
CompanyUnited States
Vascular Therapies develops one asset, in phase 3 (sirolimus in aged). Mostly small molecule acting on autophagy, mTOR signalling and MTOR; based in the United States.
- 1
- Asset
- Furthest
- Phase 3
- 2
- Trials
- 0
- Signals
Pipeline
1Lowers mTOR to help cells clear damage, repair, and stay functional longer.
Phase 3, Small molecule, Autophagy, mTOR signalling, aged, aging
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms7
- Trials2
- Signals5
- Similar companies6
Updated 10 Oct 2026 · 54 sources